Therapy for alpha-galactosidase A deficiency

Details for Australian Patent Application No. 2008200265 (hide)

Owner Shire Human Genetic Therapies, Inc.

Inventors Selden, Richard F; Borowski, Marianne; Gillespie, Frances P; Kinoshita, Carol M; Treco, Douglas A; Williams, Melanie D

Agent Griffith Hack

Pub. Number AU-B-2008200265

Parent 2003220717

Filing date 18 January 2008

Wipo publication date 7 February 2008

Acceptance publication date 28 June 2012

International Classifications

C12N 9/40 Enzymes, e.g. ligases (6.) - acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase

A61K 38/47 Medicinal preparations containing peptides

A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

C12N 5/10 Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 15/56 Mutation or genetic engineering - acting on glycosyl compounds (3.2), e.g. amylase, galactosidase, lysozyme

C12N 15/62 Mutation or genetic engineering - DNA sequences coding for fusion proteins

Event Publications

7 February 2008 Application Open to Public Inspection

  Published as AU-B-2008200265

7 February 2008 Complete Application Filed

28 June 2012 Application Accepted

  Published as AU-B-2008200265

25 October 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008200266-Refractory material for cement industry kilns and use thereof

2008200264-Switch